Connect with us


Using AI to Improve Chronic Disease Outcomes

By Bob Matthews This article reports the results of a study that follows a multi-year, pragmatic clinical trial in a real world, community based primary…



By Bob Matthews

This article reports the results of a study that follows a multi-year, pragmatic clinical trial in a real world, community based primary care. What started as a quality project evolved to include the development and deployment of Artificial Intelligence (AI) decision support to guide medication choices when treating hypertension (HTN). Results show that primary care physicians significantly improved HTN outcomes as compared to the national average of success.  All patients with a hypertension diagnosis were tracked across three years–including the COVID pandemic period. Of the 13, 441 HTN patients 94% had a blood pressure “at goal” (i.e. less than 140/90)–as of their last clinician visit. The last published study of US blood pressure control which occurred prior to the pandemic was 44%.

Because the use of AI in primary care is novel as of this writing, the concept of AI is often unfamiliar to many practicing clinicians and medical group leaders. This paper defines a threshold between simpler versions of decision support for clinicians versus AI level decision support. The paper also distinguishes between sources of AI including machine learning and other forms of AI that do not involve machine learning.

AI in medicine

AI is suited to a wide variety of use cases in healthcare (e.g., basic science research, genetics, epidemiology, pharmacological innovation, diagnosis and treatment). This project involves AI as a clinical decision support.

Not all decision support qualifies as AI. To date, most computer-based decision support in primary care has been based upon basic computations and “if/then” logic. Electronic Health Records (EHRs) are programmed to remind practitioners that an A1c or colonoscopy is overdue, for example. An EHR may point out that a patient with hypertension has not yet had an ACE/ARB prescribed. In some EHRs, a person must create the reminder and in other instances, the computer system is programmed to track one or more variable and send a message about the result.  Generally speaking, basic decision support is not dynamic.

AI begins when decision support is dynamic in that its actions or recommendations are based upon multiple–potentially hundreds or more–variables, each with potentially many different values. Changes in a value in even one variable can result in changes to the entire decision model and result. Thus, the relationship of the variables is dynamic – as one changes, the entire solution can change. For example, the AI solution for recommending precise HTN medications includes over 300 million permutations, and for Heart Failure with Reduced Ejection Fraction (HFrEF) solution there are over 850 million permutations. This is far beyond the capabilities of “if/then” logic in part because no one could map all those decision points.

Credit: Nikita John Creagh / Getty Images

Machine learning vs. algorithm based

Many believe that all AI involves machine learning but that is not so. In business and industry there are many problems for which vast amounts of data are available. Data scientists write programs directing computers to process through large numbers of data fields, each of which may have very large data sets, searching for patterns that reveal meanings that were not previously obvious. These could be “cause and effect” meanings, image recognition, predictive analytics or it can include creative efforts to identify elements of a solution opportunity.

Such an approach is called machine learning in that the computer programmer includes instructions to the application to learn how to improve its analysis through “experience.” The human operator may or may not have had a hypothesis at the start of the project.

All machine learning is AI but not all AI is machine learning. In some use cases, either there isn’t enough data available for machine learning and/or the data is so fraught with error, missing elements, inconsistencies, etc. that machine learning cannot reliably work. Medicine has this problem as is evidenced by the vast amounts of errors in EHR data.

In these instances where machine learning is not yet an option, the alternative is to build sophisticated mathematical algorithms to gather and organize the data and to define parameters and other “cognitive” processes to perform specific analyses as required to improve the precision of solutions. The AI tool described in this paper–which is called the MedsEngine–is an algorithm-based AI application.

Managing chronic diseases

Primary care is organized around three aspects of care: (1) acute care, (2) wellness and preventive care and (3) the management of chronic diseases.

While all three of these are important, the timely diagnosis and effective management of chronic disease has a special bearing on the individual health status of patients and the total cost of care across the US health system. It is well documented that the downstream “costs” to patient mortality and morbidity from poorly controlled hypertension, diabetes, lipids, heart failure, etc. can be devastating to the patient and expensive to the system.  Eighty-five percent (85%) of all US health spending is for patients with chronic diseases1.

Worse, as the COVID pandemic revealed, minority, poor and other underserved patients have less well controlled chronic diseases2 which, in turn, results in greater instances of severe illness and death from viral and other co-morbid threats.

The most common chronic diseases (i.e., hypertension, cholesterol, diabetes, CKD, vascular diseases, asthma, heart failure, COPD, anxiety, depression, arthritis and osteoporosis) are most often managed by primary care providers who may be physicians, nurse practitioners or physicians’ assistants. The goals for treatment are evidence-based standards (EBS) for care. In addition to defining “controlled,” some EBS prescribe a very specific treatment pathway to control. Others have a generalized pathway with various options, and some provide suggestions to consider when selecting therapies.

Given the ubiquity of EHRs, it is now possible to calculate the percent of patients who achieve control for most diseases.

Unfortunately, it is not common practice in most medical groups to do so. There are national studies measuring the success of chronic disease care for some diagnoses. In general, the results are disheartening.

Hypertension remains US healthcare’s biggest failure

The Centers for Disease Control and Prevention (CDC)3 finds that hypertension (HTN) is by far the most common chronic disease, affecting 47% of US adults–116 million Americans. Only 24% of these patients have achieved control. HTN’s sequelae include many debilitating and costly medical problems including death, heart attack, stroke, renal damage or failure, atrial fibrillation, heart failure, etc. Hypertension’s costs are estimated to be $131 billion to $198 billion per year4.

For over ten years there have been a host of efforts to improve HTN outcomes including the CDC’s Million Hearts campaign, the Surgeon General’s Call to Action to Control Hypertension, the National Roundtable to Control Hypertension, various programs sponsored by the American Heart Association, the American Medical Association and the American College of Cardiology. Despite all these, blood pressure control rates are declining, not improving.

In 2013-14, CDC data showed that 53.9% of HTN patients had a blood pressure of <140/90. An analysis of the NHANES5 data reveals that in 2018 44% of patients with hypertension had a BP of <140/90. Considering that the American College of Cardiology (ACC) and American Heart Association (AHA) propose a goal of 130/80, this is sad.

America is confronting significant evidence of racial, ethnic and economic inequity in healthcare. Ogunniyi, et al6 just published very damning data showing that African American and other minorities are more likely to have HTN, less likely to receive effective treatment, less likely to have their HTN controlled and, therefore, more likely to die or have serious health degradations.

The chronic disease outcomes problem is not limited to HTN.  Only 26% of patients with diabetes7 had blood pressure, LDL and A1c simultaneously controlled on their last visit. The CHAMP–HF study8 showed an amazing finding–only 1.1% of heart failure with reduced ejection fraction (HFrEF) patients were prescribed effective doses of all three or four of the key therapeutic agents as recommended by the Heart Failure Society of America and the American College of Cardiology (ACC). There is little reason to hope that patients with COPD, asthma or other chronic diseases are properly classified and on the correct medications per the EBS.

The management of hypertension–or any other chronic disease –varies enormously by physician. So, too, do the percent of patients successfully treated to the EBS goal. Physician group leadership may educate and promote the use of decision trees, but success has been elusive.

Defining the problem and solution approach

It is axiomatic among quality experts that the more complex the work is, the greater the need for standard processes to achieve high success rates. Conversely, without solid processes, high levels of quality cannot be maintained, especially across large numbers of operators. There is no reason to believe that physicians are the exception.

Historically quality improvement efforts were measured on two output goals: (1) reliably achieving the quality target or goal metric(s) over time and (2) reducing the variability between operators (in this instance, doctors or other providers).  COVID has raised a third goal in our consciousness: (3) improvements should be effective in minority patients and socio-economically challenged populations.

David Nash9,10 has written extensively about using quality theory and tools in medical care. Nash defines unwarranted variability in how physicians treat patients as a core problem obstructing improvements in healthcare quality. Brett James11, a pioneer in integrating quality theory and practice into clinical medicine, also finds that variability between operators is a source of error in healthcare.

This study measures the results of a quality improvement project which, over time, expanded to an AI effort. The parties are PriMED Physicians, a community based, independent physician group in Dayton, Ohio with 50 physicians and MediSync, the Cincinnati, Ohio company that has provided comprehensive management to PriMED for 25 years. This study is about HTN but the AI solution extends to diabetes, cholesterol and HFrEF. At the outset PriMED set a target that 90% of all patients with a given chronic disease would achieve the evidence-based defined outcome. For HTN, the goal is a BP of <140/90 but that goal is now under review and may lowered to BP <130/80 for at least some patients.

An analysis was conducted to identify reasons why blood pressures fail to meet the desired goals. As is common in quality theory and practice, the analysis included both the positive requirements–what must go right–and the negative–what could go wrong?

In quality theory, identifying the most significant sources of error organizes the search for solutions. Obviously, the medical challenges or complexity vary by disease. Some common problems occur across diseases, but one stands out. Precise advice about medication selection always involves gathering and processing a huge number of variables. Given the known limits of human cognition, this complexity is a major obstacle to improvement.

For example, for HTN the medication recommendations now include 13 classes of drugs. The 13 classes are not used equally but all are used regularly, at least in some specific circumstances. In interviews with physicians most use 3 to 6 classes of anti-hypertensive agents–often referred to as their “go to” or “favorites.” Not only were the additional classes not used, their mechanism of operation and effect on the pathophysiology of disease is also unfamiliar to many physicians and APPs. It was determined that the “complexity” had to be solved to help doctors and APPs make better medication choices in order to get better chronic outcomes12.

Seeking focus, two essential steps to improving chronic outcomes were developed:

  1. Assist the provider to identify the best medication option(s) with precision and, when multiple medications are indicated, a specific order; and 2. Assist in engaging patients in a manner that increases their participation in therapy, including filling prescriptions and regularly taking medicines, lifestyle accommodations, etc. This paper addresses the first task–assisting providers to select the precise medications–because that is where AI makes its greatest contribution.

Deconstructing blood pressure management

In quality practice, an “outcome metrics” is the measure of quality that occurs at the conclusion of a process. Thus, outcome metrics are, in turned, the result of other, “upstream” processes or variables which are called driver metrics. High blood pressure is an outcome metric in that it manifests other, upstream or “driver” problem(s). The search into causes of high blood pressure in the hopes of finding additional levers to improve control.

The upstream variables that cause high blood pressure are vasoconstriction, high heart rate, high stroke volume and elevated fluid levels13. Hypertension can be caused by any one of these “drivers” or by a combination of two, three or all four of them, which are call “mixed hemodynamic.” When these hemodynamic parameters are properly controlled, the blood pressure is most often controlled as well.

There is rich literature about the effects of various pharmaceutical agents on vasoconstriction, heart rate, stroke volume and fluid status. Using a relatively inexpensive, FDA approved, in-office test called Impedance Cardiography (ICG) provided quantification of the hemodynamic parameters (i.e., vasoconstriction, rate, stroke volume and intravascular fluid status). Based on the ICG hemodynamic data, physician focus can be guided to the medications best able to treat each patient’s high blood pressure. The first generation, “paper and pencil” solution mapped the suitability of each major class of medication to the hemodynamic factors underlying blood pressure but was limited to a static approach.

From quality improvement process to AI

Over time the HTN Process was improved by adding additional clinical variables to the selection of best medications for a patient. For example, an algorithm was created to measure the effects of 26 factors to include demographics (i.e., age, African American) and co-morbid diagnoses (diabetes, BPH, CKD, etc.) to understand how each condition might affect the potential use of a given drug or drug class when treating blood pressure. Co-morbid conditions can increase, decrease, prevent, change the order of use of drug class(es) as well as indicate when multiple drugs are needed and alert to unusual circumstances.

At this point, paper and pencil process tools were no longer helpful as the number of permutations became astronomical. In the era of EHRs physicians complained that the paper and pencil decision tools were a burden. This led to the development of the AI application, the MedsEngine.

The shift to AI added additional opportunities to add precision. For example, in earlier solutions physicians used an “eyeball” evaluation of graphs showing the ICG results. With AI it was possible to feed the raw ICG data and develop a mathematical model to measure each ICG parameter against an ideal and against each other. This provided better insight into the many patients whose hypertension involved a mixture of hemodynamic causes.

The current AI driven precision medication recommendation for hypertension includes over 300 million permutations, a level of complexity that is known to be beyond human cognition, especially when physicians and APPs are working in 15-to-30-minute time slots.

How it works in daily practice

Because the EHRs available today use legacy technologies that are not capable of the kinds of computation that the MedsEngine performs, the AI was developed as a cloud technology using Microsoft’s Azure environment. Microsoft Azure is widely used in other economic sectors and in applications by some of the world’s biggest companies (i.e., Boeing, Verizon, BMW, etc.).

As a Cloud technology, no processors or databases need be installed onsite. Rather, a medical groups’ EHR is connected to the MedsEngine using the federally mandated inter-operability standards known as FHIR and Smart on FHIR. Because CMS required that all EHRs must be FHIR and Smart on FHIR enabled, the MedsEngine is EHR agnostic. The FHIR standards now make it possible to link our technology to any EHR in hours, a task that would have taken months prior to FHIR.

Clinicians simply hit a button inside the EHR screen environment and, without manually signing out or in to any technology, a vast amount of data specific only to the patient in question is raised to the MedsEngine including diagnosed problems, drug list, test and lab results, allergies, past medical and surgical history, demographics, etc. The MedsEngine presents a “validation” screen where the provider can click to amend any patient information that is either missing or incorrect from the EHR.  Then the MedsEngine processes the data and the medication recommendations are returned within 1-2 seconds inside the EHR. The physician, of course, determines whether to follow MedsEngine’s recommendations.


In quality theory there are two key measures of success: (1) achieving the target goal and (2) reducing variability among operators–physicians and licensed providers, in this instance.  Decreases in variability can be measured by reductions in the standard deviations of success rates across operators. Process capability is the ability of the process to achieve its stated goal(s).  Experienced quality experts believe that it is easier to improve the success rate of a process than to reduce variability across providers but the two must work in tandem. A high rate of variability precludes a high rate of success.

As stated earlier, the goal for each chronic disease state is that 90% of all diagnosed patients achieve the evidence-based standard for “control.” In blood pressure this is currently a BP of <140/90 using the National Quality Foundation (NQF) measurement procedures adopted by CMS and NCQA.

Addressing racial and socio-economic disparities of care

COVID has further revealed significantly inferior chronic disease outcomes due to racial and economic disparities in care and life circumstances. By contrast, PriMED’s success rate for controlling blood pressure in African American HTN patients is currently 92.2%.

Isolating a family practice physician whose practice is limited to an underserved African American community that is 85% African American with 59% of patients have Medicaid, Medicare or are uninsured, the following percent of well controlled HTN is remarkable. (Note that this physician’s results are also included in Figures 1 and 2.)

Figure 1. Group-wide percent of all 13,441 HTN patients
Figure 1. Group-wide percent of all 13,441 HTN patients with BP of <140/90 at last visit by month from January 2019 through November 30, 2021. Note that this period includes the COVID pandemic. These outcomes are exactly 50 percentage points higher–more than double – the last published national average of 44% HTN patients with BP of <140/90.
Figure 2. Reduced variability: Each physician is represented by a trend line reflecting the percent of that physician’s HTN patients with BP of <140/9 as of the last visit by month. Early in 2019 there is significant variability among physicians’ outcomes. This tightens up into late 2019 and early 2020. As the COVID pandemic unfolds, the variability increases notably only to tighten again towards the latter half of 2021, despite the fact that COVID is an ongoing event. As of November 30, 2021, all but one PriMED physician was above the group mean or within 5% of the group mean. The standard deviation of individual physician outcomes is 3.9%.
Figure 3. The distribution of systolic blood pressures
Figure 3. The shows the distribution of systolic blood pressures for 31,975 HTN patient encounters from January 1 through November 30, 2021.
Figure 4. Percent blood pressure-controlled patients
Figure 4. Percent blood pressure-controlled patients in a socio-economically disadvantaged neighborhood of whom 85% are African American and 59% have Medicaid, Medicare, or are uninsured.


Many medical groups who have made hypertension improvement efforts have become frustrated at the difficulty of achieving results higher than 70% success across the HTN population.

Studies have found that physicians and APPs are writing incorrect medications when treating chronic diseases like hypertension. And no wonder. It is long past time for US healthcare to adopt and deploy contemporary quality theory, insist upon the expansive use of processes to master complexity, stop relying upon human beings to do impossible calculations and manage lengthy decision trees from memory and to embed processes in AI applications.

This work shows how a combination of processes embedded in an AI technology, such as the MedsEngine, helps physicians achieve nationally remarkable outcomes, do so consistently and with significantly reduced variation between providers. As of November 30, 2021, PriMED’s blood pressure control rate for the entire HTN patient population was 94%. Getting the medications right matters.

blood pressure illustration
Credit: Irina Strelnikova / Getty Images

National efforts convened by the CDC and other organizations to improve blood pressure outcomes have not been successful to date. Even before the pandemic, hypertension patients’ blood pressures of <140/90 had declined from 53.9% success to 44% success from 2014 to 2018. Recent studies14 find that COVID has increased average blood pressures in HTN patients and, thus reduced the percent of HTN patients whose blood pressure is controlled. Based upon the literature, it should be expected that well controlled hypertension patients have fewer co-morbid complications, successfully maintain a higher standard of health across the population and have a lower total cost of care. In fact, PriMED’s total cost of care is approximately 20% less than our regional average total cost per patient.

This paper demonstrates that in a real-world clinical environment, AI technologies improved physician decision making, improved patient outcomes, and lowered total costs – all key ingredients to achieving the triple aim.


1. Holman HR. The Relation of the Chronic Disease Epidemic to the Health Care
Crisis. ACR Open Rheumatol. 2020;2(3):167-173. doi:10.1002/acr2.11114.
2. Fouad MN, Ruffin J, Vickers SM. COVID-19 Is Disproportionately High in
African Americans. This Will Come as No Surprise…. Am J Med. 2020;133(10):e544-e545. doi:10.1016/j.amjmed.2020.04.008.
3. The Centers For Disease Control and Prevention, High Blood Pressure, Hypertension Statistics and Maps. Accessed December 30, 2021
4. CDC, Associate Director for Policy and Strategy, POLARIS, Health Topics – High Blood Pressure. Accessed December 30, 2021.
5 Muntner P, Hardy ST, Fine LJ, et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324(12):1190–1200. doi:10.1001/jama.2020.14545.
6. Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, Ethnicity, Hypertension, and Heart Disease: J Am Coll Cardiol. 2021; 78(24):2460-2470,
7. Chen Y, Rolka D, Xie H, Saydah S. Imputed State-Level Prevalence of Achieving Goals To Prevent Complications of Diabetes in Adults with Self-Reported Diabetes – United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020;69:1665-1670. DOI:
8. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure With
Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070. PMID: 30025570.
9. Nash DB, Joshi M, Ransom ER, Ransom SB. (eds)The Healthcare Quality Book—
Vision, Strategy and Tools. 4th ed, Health Administration Press, Chicago, IL 2019.
10. Kumar S., Nash DB. Demand Better, Second River Healthcare Press, Bozeman MT,
11. Goitein, L, James, Brent. Standardized Best Practices and Individual Craft-Based
Medicine: A Conversation About Quality. JAMA Internal Medicine. 176. 10.1001/ja
mainternmed. 2016.1641. 2016.
12. The complexity problem is common to all chronic disease management. For
example, the 2018 AHA and ACC guidelines for cholesterol management, the
American Diabetes Association guidelines for diabetes management and the GOLD standard for COPD management will show hundreds of pages of text, decision trees that go on for up to 17 pages, numerous variables, formulae, etc. It is not possible to memorize or apply these complex standards from memory and achieve very high levels of success..
13. Hector O. Ventura, Sandra J. Taler, John E. Strobeck, Hypertension as a hemod
ynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making, American Journal of Hypertension, Volume 18, Issue
S2, February 2005, Pages 26S–43S,
14. Laffin LJ, Kaufman HW, Chen Z, et al. Rise in Blood Pressure Observed Among US
Adults During the COVID-19 Pandemic. Circulation. 2021 Dec 6. doi: 10.1161/
CIRCULATIONAHA.121.057075. Epub ahead of print. PMID: 34865499.


Bob Matthews is a leader of physician groups and is Black Belt trained in the Six Sigma quality methods which he and his team use to create new methods and processes to help patient’s achieve better health outcomes at a lower total cost of care. Bob co-leads a team creating AI solutions to help physicians achieve outstanding chronic disease outcomes.

The post Using AI to Improve Chronic Disease Outcomes appeared first on Inside Precision Medicine.

Read More

Continue Reading


I’m headed to London soon for #EUBIO22. Care to join me?

Adrian Rawcliffe
It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re…



Adrian Rawcliffe

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Kate Bingham

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

After that I’ve teed up two webinars on mRNA research — with some of the top experts in Europe — and the oncology scene, building better CARs in Europe.

That afternoon, we’ll switch to a live/streaming hybrid event, with a chance to gather once again now that the pandemic has faded. I’ve recruited a panel of top biotech execs to look at surviving the crazy public market, with Adrian Rawcliffe, the CEO of Adaptimmune, SV’s Kate Bingham, Mereo CEO Denise Scots-Knight and Andrew Hopkins, chief of Exscientia.

Andrew Hopkins
Denise Scots-Knight

That will be followed by my special, live fireside chat with Susan Galbraith, the oncology R&D chief at AstraZeneca. And then we’ll turn to Nooman’s panel, where he’ll be talking with Katya Smirnyagina with Oxford Science Enterprises, Maina Bhaman with Sofinnova Partners and Rosetta Capital’s Jonathan Hepple about navigating the severe capital headwinds.

You can review the full schedule and buy tickets here and review everything we have planned. It will be a packed day. I hope to see you there. It’s been several years now since I’ve had a chance to meet people in the Golden Triangle. I’m very much looking forward to it.

Read More

Continue Reading


We can turn to popular culture for lessons about how to live with COVID-19 as endemic

As COVID-19 transitions from a pandemic to an endemic, apocalyptic science-fiction and zombie movies contain examples of how to adjust to the new norm…




An endemic means that COVID-19 is still around, but it no longer disrupts everyday life. (Shutterstock)

In 2021, conversations began on whether the COVID-19 pandemic will, or even can, end. As a literary and cultural theorist, I started looking for shifts in stories about pandemics and contagion. It turns out that several stories also question how and when a pandemic becomes endemic.

Read more: COVID will likely shift from pandemic to endemic — but what does that mean?

The 2020 film Peninsula, a sequel to the Korean zombie film, Train to Busan, ends with a group of survivors rescued and transported to a zombie-free Hong Kong. In it, Jooni (played by Re Lee) spent her formative years living through the zombie epidemic. When she is rescued, she responds to being informed that she’s “going to a better place” by admitting that “this place wasn’t bad either.”

Jooni’s response points toward the shift in contagion narratives that has emerged since the spread of COVID-19. This shift marks a rejection of the push-for-survival narratives in favour of something more indicative of an endemic.

Found within

Contagion follows a general cycle: outbreak, epidemic, pandemic and endemic. The determinants of each stage rely upon the rate of spread within a specified geographic region.

Etymologically, the word “endemic” has its origins with the Greek words én and dēmos, meaning “in the people.” Thus, it refers to something that is regularly found within a population.

Infectious disease physician Stephen Parodi asserts that an endemic just means that a disease, while still prevalent within a population, no longer disrupts our daily lives.

Similarly, genomics and viral evolution researcher Aris Katzourakis argues that endemics occur when infection rates are static — neither rising nor falling. Because this stasis occurs differently with each situation, there is no set threshold at which a pandemic becomes endemic.

Not all diseases reach endemic status. And, if endemic status is reached, it does not mean the virus is gone, but rather that things have become “normal.”

Survival narratives

We’re most likely familiar with contagion narratives. After all, Steven Soderbergh’s 2011 film Contagion, was the most watched film on Canadian Netflix in March 2020. Conveniently, this was when most Canadian provinces went into lockdown during the early stages of the COVID-19 pandemic.

A clip from the film Contagion showing the disease spreading throughout the world.

In survival-based contagion narratives, characters often discuss methods for survival and generally refer to themselves as survivors. Contagion chronicles the transmission of a deadly virus that is brought from Hong Kong to the United States. In response, the U.S. Centers for Disease Control is tasked with tracing its origins and finding a cure. The film follows Mitch Emhoff (Matt Damon), who is immune, as he tries to keep his daughter safe in a crumbling Minneapolis.

Ultimately, a vaccine is successfully synthesized, but only after millions have succumbed to the virus.

Like many science fiction and horror films that envision some sort of apocalyptic end, Contagion focuses on the basic requirements for survival: shelter, food, water and medicine.

However, it also deals with the breakdown of government systems and the violence that accompanies it.

A “new” normal

In contrast, contagion narratives that have turned endemic take place many years after the initial outbreak. In these stories, the infected population is regularly present, but the remaining uninfected population isn’t regularly infected.

A spin-off to the zombie series The Walking Dead takes place a decade after the initial outbreak. In the two seasons of The Walking Dead: World Beyond (2020-2021) four young protagonists — Hope (Alexa Mansour), Iris (Aliyah Royale), Silas (Hal Cumpston) and Elton (Nicolas Cantu) — represent the first generation to come of age within the zombie-infested world.

The four youth spent their formative years in an infected world — similar to Jooni in Peninsula. For these characters, zombies are part of their daily lives, and their constant presence is normalized.

The trailer for the second season of AMC’s The Walking Dead: World Beyond.

The setting in World Beyond has electricity, helicopters and modern medicine. Characters in endemic narratives have regular access to shelter, food, water and medicine, so they don’t need to resort to violence over limited resources. And notably, they also don’t often refer to themselves as survivors.

Endemic narratives acknowledge that existing within an infected space alongside a virus is not necessarily a bad thing, and that not all inhabitants within infected spaces desire to leave. It is rare in endemic narratives for a character to become infected.

Instead of going out on zombie-killing expeditions in the manner that occurs frequently in the other Walking Dead stories, the characters in World Beyond generally leave the zombies alone. They mark the zombies with different colours of spray-paint to chronicle what they call “migration patterns.”

The zombies have therefore just become another species for the characters to live alongside — something more endemic.

The Walking Dead, Fear the Walking Dead (2015-), Z Nation (2014-18), and many other survival-based stories seem to return to the past. In contrast, endemic narratives maintain a present and sometimes even future-looking approach.

Learning from stories

According to film producer and media professor Mick Broderick, survival stories maintain a status quo. They seek a “nostalgically yearned-for less-complex existence.” It provides solace to imagine an earlier, simpler time when living through a pandemic.

However, the shift from survival to endemic in contagion narratives provides us with many important possibilities. The one I think is quite relevant right now is that it presents us with a way of living with contagion. After all, watching these characters survive a pandemic helps us imagine that we can too.

Krista Collier-Jarvis does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading


Xi Reemerges In 1st Public Appearance After ‘Coup’ Rumors

Xi Reemerges In 1st Public Appearance After ‘Coup’ Rumors

So much for the "coup in China" and "Xi is missing" rumor mill of the past week,…



Xi Reemerges In 1st Public Appearance After 'Coup' Rumors

So much for the "coup in China" and "Xi is missing" rumor mill of the past week, which at one point saw Chinese President Xi Jinping's name trending high on Twitter...

"Chinese President Xi Jinping visited an exhibition in Beijing on Tuesday, according to state television, in his first public appearance since returning to China from an official trip to Central Asia in mid-September – dispelling unverified rumours that he was under house arrest."

He had arrived in Samarkand, Uzbekistan on September 15 - and attended the days-long Shanghai Cooperation Organization (SCO) summit - where he met with Russian President Vladimir Putin, among others.

Xi is "back"...image via state media screenshot

Importantly, it had been his first foreign trip in two years. Xi had not traveled outside of the country since before the Covid-19 pandemic began.

But upon returning the Beijing, he hadn't been seen in the public eye since that mid-September trip, fueling speculation and rumors in the West and on social media. Some pundits floated the idea that he had been under "house arrest" amid political instability and a possible coup attempt.

According to a Tuesday Bloomberg description of the Chinese leader's "re-emergence" in the public eye, which has effectively ended the bizarre rumors

Xi, wearing a mask, visited an exhibition in Beijing on Tuesday about China's achievements over the past decade, state-run news outlet Xinhua reported. The Chinese leader was accompanied by the other six members of the Politburo Standing Committee, a sign of unity after rumors circulated on Twitter about a challenge to his power.

He'll likely cinch his third five-year term as leader at the major Chinese Communist party’s (CCP) meeting on October 16. The CCP meeting comes only once every half-decade.

What had added to prior rumors was the fact that the 69-year old Xi recently undertook a purge of key senior security officials. This included arrests on corruption charges of the former police chiefs of Shanghai, Chongqing and Shanxi.

More importantly, former vice minister of public security Sun Lijun and former justice minister Fu Zhenghua were also sacked and faced severe charges.

Concerning Sun Lijun, state media made this shocking announcement a week ago: "Sun Lijun, former Chinese vice minister of public security, was sentenced to death with a two-year reprieve for taking more than 646 million yuan of bribes, manipulating the stock market, and illegally possessing firearms, according to the Intermediate People's Court of Changchun in Northeast China's Jilin Province on Friday." The suspended death sentence means he'll spend life in prison.

Tyler Durden Wed, 09/28/2022 - 14:05

Read More

Continue Reading